The new state-of-the-art cGMP manufacturing suite strengthens Dipharma’s CDMO offering and completes the range of exclusive services, ensuring continuity across the whole lifecycle of Customers’ molecules, from preclinical to commercial stage.
The QC laboratory is designed and equipped according to latest pharmaceutical quality standards, with full CFR21 compliance for Data Integrity management.
“The new suite marks the achievement of a key milestone within the Exclusive Synthesis growth strategy and reinforces the company’s value proposition to provide reliable innovative solutions to customers: Dipharma Group is now able to cover the whole pharmaceutical chemistry services spectrum, from discovery to marketed drugs,” commented Mr. Jorge Nogueira, CEO of Dipharma Francis S.r.l. “Furthermore, I am pleased to highlight that, with the construction of the new kilolab, Dipharma implements cGMP capability at its American subsidiary Kalexsyn Inc., enhancing its range of exclusive services from CRO to CDMO.”
With an engineering batch already scheduled for production, Dipharma is currently assembling all documents required by FDA for Drug Establishment Registration.
